Absolute neutrophil count (ANC) >= 1000/uLXx_NEWLINE_xX* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXFor patients with solid tumors without known bone marrow involvement: peripheral absolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXSTEP I: Absolute neutrophil count >= 1000 cells/mm^3 (obtained within 28 days prior to randomization)Xx_NEWLINE_xXSTEP II: Absolute neutrophil count >= 1000 cells/mm^3 (within 28 days prior to randomization to Step II)Xx_NEWLINE_xXNeutrophils >= 1000/uLXx_NEWLINE_xXPeripheral absolute neutrophil count (ANC) >= 1000/uLXx_NEWLINE_xXPeripheral absolute neutrophil count (ANC) >= 1000/uL for patients with solid tumors without bone marrow involvementXx_NEWLINE_xXWithin 10 days of treatment initiation: Absolute neutrophil count (ANC) >= 1000 cells/mm^3 (or >= 750 in subjects with bone marrow involvement)Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3, independent of growth factor support, documented within 14 days of registrationXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/uLXx_NEWLINE_xXAbsolute neutrophil count ? 1000/?L, with or without cytokine supportXx_NEWLINE_xXThe absolute neutrophil count (ANC) >= 1000/mm^3 without colony stimulating factor supportXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) ? 1000/mm3 2) Insufficient hepatic and renal function at screening:Xx_NEWLINE_xXAbsolute neutrophil count (ANC) ? 1000 cells/mm3Xx_NEWLINE_xXAbsolute neutrophil count > 1000 /uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) ? 1000/mm3;Xx_NEWLINE_xXAbsolute neutrophil count >= 1000/mm^3 without colony stimulating factor support, within 14 days before the first dose of cabozantinibXx_NEWLINE_xXAbsolute neutrophil count >= 1000 cells/mm^3Xx_NEWLINE_xXPeripheral absolute neutrophil count (ANC) >= 1000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) ? 1000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) ? 1000 cells/?LXx_NEWLINE_xXObtained =< 21 days prior to registration: absolute neutrophil count (ANC) >= 1000/uLXx_NEWLINE_xXANC ? 1000/µLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXPeripheral absolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXPeripheral absolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXPeripheral absolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count >= 1000/ mm^3 (unsupported) and documented within 14 days prior to registration and within 14 days prior to the start of treatmentXx_NEWLINE_xXDocumented within 14 days of registration: Absolute neutrophil count >= 1000/ul (unsupported)Xx_NEWLINE_xXPeripheral absolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1000/mcLXx_NEWLINE_xXObtained =< 21 days prior to registration and confirmed prior to the first dose of study drug: Absolute neutrophil count (ANC) >= 1000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXANC > 1000/µLXx_NEWLINE_xXAbsolute neutrophil count >= 1000/mm^3 (performed within 14 days of treatment initiation)Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3, obtained =< 14 days prior to registrationXx_NEWLINE_xXAbsolute neutrophil count > 1000/mm3,Xx_NEWLINE_xXAbsolute neutrophil count >= 1000 cells/uLXx_NEWLINE_xXINCLUSION CRITERIA FOR STRATUM C: Absolute neutrophil count >= 1000 cells/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1000/mm^3 in the absence of bone marrow involvement; patients with bone marrow involvement are not required to have a minimum absolute neutrophil countXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/uLXx_NEWLINE_xXAbsolute neutrophil count greater than 1000/mm^3 without support of filgrastimXx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1000/mm^3.Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1000Xx_NEWLINE_xXAbsolute neutrophil count greater than 1000/mm^3 without the support of filgrastimXx_NEWLINE_xXObtained =< 14 days prior to registration: Absolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXStable engraftment, as defined by absolute neutrophil count (ANC) >= 1000/mm^3 and platelets >= 25,000/mm^3Xx_NEWLINE_xXPART I: Absolute neutrophil count (ANC) >= 1000 cells/mm^3Xx_NEWLINE_xXPART II: ANC >= 1000 cells/mm^3Xx_NEWLINE_xXAbsolute granulocyte count >= 1000 K/uLXx_NEWLINE_xXAbsolute neutrophil count greater than 1000/mm^3 without the support of filgrastimXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000 cells/uLXx_NEWLINE_xXAbsolute neutrophil count greater than 1000/mm^3 without support of filgrastimXx_NEWLINE_xXNeutropenia (absolute neutrophil count [ANC] < 1000 cells/ul)Xx_NEWLINE_xXPeripheral absolute neutrophil count (ANC) >= 1000/mm^3.Xx_NEWLINE_xXAbsolute neutrophil count > 1000/mm^3 without the support of filgrastimXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000 per mm^3 obtained within 14 days prior to initiating study treatment.Xx_NEWLINE_xXObtained ? 14 days prior to registration: Absolute neutrophil count (ANC) ? 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) < 1000/mm^3, per principal investigator (PI) discretion if thought to be related to underlying myelomaXx_NEWLINE_xXAbsolute neutrophil count ? 1000/mcLXx_NEWLINE_xXAbsolute neutrophil count < 1000 cells/mm^3. No growth factors allowed within 1 week of enrollmentXx_NEWLINE_xXAbsolute neutrophil count > 1000/mm^3 without the support of growth factorsXx_NEWLINE_xXGranulocyte count ? 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) ? 1000/uL, with or without chronic granulocyte growth factor supportXx_NEWLINE_xXAbsolute neutrophil count ? 1000/mm^3, unless due to disease involvement in the bone marrowXx_NEWLINE_xXWithin 7 days of enrollment and with 24 hours (h) of starting lymphodepleting chemotherapy: Absolute neutrophil count (ANC) >= 1000/mm^3.Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,000/mm^3, performed within 14 days prior to day 1 of protocol therapy\r\n* Filgrastim can be given prior to enrollment to achieve target ANC >= 1000/uLXx_NEWLINE_xXSTRATUM A: Absolute neutrophil count (ANC) >= 1000/mm^3 without growth factor support within 7 days of the testXx_NEWLINE_xXPeripheral absolute neutrophil count (ANC) ? 1000/mm3 andXx_NEWLINE_xXAbsolute neutrophil count greater than 1000/mm^3 without support of filgrastimXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3 independent of growth factor supportXx_NEWLINE_xXAbsolute neutrophil count >= 1000/mm^3Xx_NEWLINE_xXPeripheral absolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count > 1000/mcLXx_NEWLINE_xXAbsolute lymphocyte count >= 1000/ulXx_NEWLINE_xXPeripheral absolute neutrophil count (ANC) >= 1000/uLXx_NEWLINE_xXAbsolute neutrophil count < 1000/uL at the screening visitXx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1000/ulXx_NEWLINE_xXAbsolute neutrophil count (ANC) < 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3 obtained =< 14 days prior to registrationXx_NEWLINE_xXGranulocyte count >= 1000/mm^3 (within 16 days before starting therapy)Xx_NEWLINE_xXAbsolute neutrophil count > 1000/mm^3 without the support of filgrastimXx_NEWLINE_xXANC (Absolute neutrophil count) >= 1000/ul (unsupported)Xx_NEWLINE_xXAbsolute neutrophil count >= 1000 cells/mm^3 within 14 days of study registrationXx_NEWLINE_xXWithin 14 days of the first dose of the study drugs: Absolute neutrophil count >= 1000/mcL.Xx_NEWLINE_xXWithin 7-10 days of study drug administration: Absolute neutrophil count >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil (ANC) count greater than 1000/ µLXx_NEWLINE_xXPeripheral Absolute neutrophil count (ANC) ? 1000/mm33Xx_NEWLINE_xXWithin 7 days (+ 3 day window) of enrollment: Absolute neutrophil count (ANC) >= 1.0 x 10^9/L (> 1000 per mm^3)Xx_NEWLINE_xXREP ELIGIBILITY: Absolute neutrophil count greater than or equal to 1000/mcLXx_NEWLINE_xXCHEMOTHERAPY/CELL INFUSION ELIGIBILITY: Absolute neutrophil count greater than or equal to 1000/mcLXx_NEWLINE_xXObtained =< 14 days prior to registration: Absolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count greater than 1000/mm^3 without the support of filgrastimXx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1000/mcLXx_NEWLINE_xXParticipants with an absolute neutrophil count (ANC) >= 1000/mm^3, within 21 days of initiation of protocol therapy; growth factor within 7 days of screening is not allowed to meet ANC eligibility criteriaXx_NEWLINE_xXParticipants with an absolute neutrophil count (ANC) < 1000/mm^3, within 21 days of initiation of protocol therapy; growth factor within 7 days of screening is not allowed to meet ANC eligibility criteriaXx_NEWLINE_xXPeripheral absolute neutrophil count (ANC) >= 1000/mm^3 within 14 days of registrationXx_NEWLINE_xXPeripheral absolute neutrophil count (ANC) ? 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count greater than or equal to 1000/mm^3 without the support of filgrastim or other growth factorsXx_NEWLINE_xXNeutrophil count >= 1000/uL prior to biopsyXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3 obtained =< 14 days prior to registrationXx_NEWLINE_xXAbsolute neutrophil count >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3 (obtained =< 14 days prior to registration)Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/uL, within 14 days of study registration (within 30 days for pulmonary and cardiac assessments)Xx_NEWLINE_xXANC ? 1000/uLXx_NEWLINE_xXAbsolute neutrophil count >=1000/mm^3 [1.0 x 10^9/ liter (L)]Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >/=1000 cells per microliter (cells/mcL) (Cohorts A, B, D, E, F)Xx_NEWLINE_xXAbsolute neutrophil count ?1000/uLXx_NEWLINE_xXFOR MULTIPLE MYELOMA ONLY: Obtained =< 14 days prior to registration: Absolute neutrophil count (ANC) >= 1000/uLXx_NEWLINE_xXTo be performed within 10 business days prior to day 1: Absolute neutrophil count (ANC) >= 1,000/mm^3; filgrastim can be given prior to enrollment to achieve target ANC >= 1000/uLXx_NEWLINE_xXWithin 14 days prior to planned start of treatment: Absolute neutrophil count (ANC) >= 1000/mm^3\r\n* Growth factor is not permitted within 14 days of ANC assessment unless cytopenia is secondary to disease involvementXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3, unless due to disease involvement in the bone marrowXx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXNeutrophil count >= 1000 prior to biopsyXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1500/mm^3; (ANC > 1000/mm^3 may be considered in special circumstances such as benign cyclical neutropenia as judged by the investigator and in discussion with the sponsor)Xx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1000/uL should be obtained within 21 days prior to enrollmentXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/uL at screening visitXx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1000/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1000 cells/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3 independent of growth factor supportXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/uL obtained =< 14 days prior to registrationXx_NEWLINE_xXAbsolute neutrophil count (ANC) < 1000/mm^3 unless lymphoma, KSHV-MCD, or KICS-relatedXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/uLXx_NEWLINE_xXAbsolute neutrophil count greater than 1000/mm^3 without the support of filgrastimXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000 (within 14 days prior to registration)Xx_NEWLINE_xXAbsolute neutrophil count greater than 1000/mm^3 without the support of filgrastimXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXPART 2 GROUP 1 INCLUSION CRITERIA: Peripheral absolute neutrophil count (ANC) >= 1000/mm^3 (1.0 x 10^9/L) without granulocyte growth factor for >= 7 daysXx_NEWLINE_xXAbsolute neutrophil count greater than 1000/mm^3 without the support of filgrastimXx_NEWLINE_xXAbsolute neutrophil count (ANC) < 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1000/uLXx_NEWLINE_xXPatients must have absolute neutrophil count (ANC) >= 1000/uL; neupogen can be given before and during treatment to achieve target ANC >= 1000/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1000/mm^3Xx_NEWLINE_xXEXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): Absolute neutrophil count (ANC) < 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3 without the support of filgrastimXx_NEWLINE_xXAbsolute neutrophil count greater than or equal to 1000/mm^3 without the support of filgrastim or other growth factorsXx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1000/uLXx_NEWLINE_xXObtained =< 14 days prior to registration: Absolute neutrophil count >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1000/mm^3 unless deemed related to lymphoma involvement in the bone marrow and felt potentially reversible by the treating physicianXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count greater than 1000/mm^3 without the support of filgrastimXx_NEWLINE_xXAbsolute neutrophil count (ANC) < 1000/mclXx_NEWLINE_xXNo significant anemia (hemoglobin below 9.0 g/dL) or neutropenia (absolute neutrophil count [ANC] < 1000/mm^3)Xx_NEWLINE_xXAbsolute neutrophil count >= 1000/?lXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/uLXx_NEWLINE_xXWithin 3 months of registration: Absolute neutrophil count (ANC) >= 1000 cells/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3; growth factor is not permitted within 14 days of neutrophil assessmentXx_NEWLINE_xXWithin 6 weeks of day 1: Absolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3 or >= 750/mm^3 in the setting of marrow involvement by disease (independent of growth factor or transfusion support)Xx_NEWLINE_xXAbsolute neutrophil count (ANC) ? 1000/mm3, independent of growth factor support;Xx_NEWLINE_xXNeutrophil count >= 1000/mm^3 (no growth factors within 5 days)Xx_NEWLINE_xXPeripheral absolute neutrophil count (ANC) greater than or equal to 1000/microLXx_NEWLINE_xXAbsolute neutrophil count (ANC) greater than or equal to 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXPeripheral absolute neutrophil count (ANC) ? 1000/mm³.Xx_NEWLINE_xXPeripheral absolute granulocyte count of > 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count > 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/ucl obtained within 28 days prior to registrationXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) of >= 1000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/uL, obtained =< 14 days prior to registrationXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/uLXx_NEWLINE_xXabsolute neutrophil count (ANC) must be greater than or equal to 1000/mm3;Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3 or >= 750/mm^3 in the setting of marrow involvement by diseaseXx_NEWLINE_xXAbsolute neutrophil count greater than 1000/mm^3 without the support of filgrastimXx_NEWLINE_xXAbsolute neutrophil count greater than 1000/mm^3 without the support of filgrastimXx_NEWLINE_xXAdequate blood cell counts (i.e. absolute neutrophil count [ANC] > 1000) at baseline, or willingness to accept supportive measures such as transfusions, filgrastim, and epoetinXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/uLXx_NEWLINE_xXAbsolute neutrophil count greater than 1000/mm^3 without the support of filgrastimXx_NEWLINE_xXAbsolute neutrophil count greater than or equal to 1000/mm^3 (Turnstile II)Xx_NEWLINE_xXAbsolute neutrophil count >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000 cells/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/ulXx_NEWLINE_xXAbsolute neutrophil count greater than or equal to 1000/mm^3 (Turnstile II)Xx_NEWLINE_xXNeutrophil count >= 1000 /uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count >= 1000/mLXx_NEWLINE_xXAbsolute neutrophil count (ANC) < 1000/mcLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000 cells/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3; this value must be obtained within four weeks before protocol entryXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3 without the support of filgrastimXx_NEWLINE_xXPatients must have absolute neutrophil count (ANC) > 1000/mclXx_NEWLINE_xXAbsolute neutrophil count (ANC) =< 1000/ulXx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1000Xx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1000Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) ?1000/mm3.Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3 obtained =< 14 days prior to registrationXx_NEWLINE_xXabsolute neutrophil count ? 1000/?L,Xx_NEWLINE_xXObtained =< 14 days prior to registration: Absolute neutrophil count (ANC) >= 1000/uL (without growth factor support)Xx_NEWLINE_xXAbsolute neutrophil count (ANC) <1000/mm3Xx_NEWLINE_xXANC >= 1000 K/CUMMXx_NEWLINE_xXAbsolute neutrophil count >1000/mm3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count greater than 1000 /mm³Xx_NEWLINE_xXObtained ? 14 days prior to registration: absolute neutrophil count (ANC) ? 1000/mm^3Xx_NEWLINE_xXWithin 7 days before the first dose of cabozantinib: The absolute neutrophil count (ANC) >= 1000/mm^3 without colony stimulating factor supportXx_NEWLINE_xXAbsolute neutrophil count greater than 1000/mm3 without the support of filgrastimXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1.0 x 10^9/L (>=1000 per mm^3).Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3 without transfusion support.Xx_NEWLINE_xXAbsolute neutrophil count (ANC) less than or equal to 1000Xx_NEWLINE_xXAbsolute Neutrophil Count (ANC) > 1000/mm3Xx_NEWLINE_xXWithin 7 days prior to study registration: Peripheral absolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/ millimeter cube (mm^3) (1.0 x 109^9/liter [L])Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXARM A: obtained =< 14 days prior to registration: \r\n* Absolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXARM B: obtained =< 14 days prior to registration: \r\n* Absolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXObtained within 14 days (or as stipulated) prior to study drug (treatment) administration: absolute neutrophil count (ANC) ? 1000 cells/ul (growth factor cannot be used within the previous 5 days)Xx_NEWLINE_xXPatients must have absolute neutrophil count (ANC) > 1000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000 x 10^9/L, unsupported by filgrastim (G-CSF) or granulocytesXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1000/mm^3Xx_NEWLINE_xXAbsolute phagocyte count (APC = neutrophils and monocytes): >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count >= 1000/mm^3Xx_NEWLINE_xXFor patients with solid tumors without bone marrow involvement: peripheral absolute neutrophil count (ANC) >= 1000/uLXx_NEWLINE_xXAbsolute neutrophil count greater than or equal to 1000/mm^3 without the support of filgrastim or other growth factorsXx_NEWLINE_xXPeripheral absolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXFor patients with solid tumors without bone marrow involvement: peripheral absolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXFor patients with solid tumors without known bone marrow involvement: peripheral absolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXPeripheral absolute neutrophil count (ANC) >= 1000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) < 1000 / mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000Xx_NEWLINE_xXAbsolute neutrophil count greater than 1000/mm^3 without the support of filgrastimXx_NEWLINE_xXAbsolute neutrophil count greater than or equal to 1000/mcLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/ulXx_NEWLINE_xXPeripheral absolute neutrophil count (ANC) >= 1000/uL (must not have received filgrastim [G-CSF] within the prior 7 days)Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/uLXx_NEWLINE_xXNeutropenia (absolute neutrophil count [ANC] < 1000 cells/ul)Xx_NEWLINE_xXParticipants with an absolute neutrophil count (ANC) < 1000/mm^3, within 21 days of initiation of protocol therapy; growth factor within 7 days of screening is not allowed to meet ANC eligibility criteriaXx_NEWLINE_xXAbsolute neutrophil count ? 1000/µLXx_NEWLINE_xXAbsolute neutrophil count ?1000 cells/mm3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3, obtained =< 21 days prior to registrationXx_NEWLINE_xXMF PATIENTS: Absolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) < 1000Xx_NEWLINE_xXAbsolute neutrophil count ? 1000 /mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) ?1000/?L.Xx_NEWLINE_xXAbsolute neutrophil count >= 1000/uLXx_NEWLINE_xXANC > 1000/mcLXx_NEWLINE_xXAbsolute neutrophil count >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) ? 1000/uLXx_NEWLINE_xXAbsolute neutrophil > 1000/uLXx_NEWLINE_xXAbsolute neutrophil count less than 1000/mm^3Xx_NEWLINE_xXANC >= 1000 cells/mm^3 (1.0 x 10^9/L)Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3 obtained =< 7 days prior to registrationXx_NEWLINE_xXAbsolute neutrophil count > 1000/?LXx_NEWLINE_xXPrior to cyclophosphamide and T cell infusions: absolute neutrophil count (ANC) =< 1000Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/uL, obtained =< 21 days prior to registration and confirmed prior to the first dose of study drugXx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1000 K/uL independent of transfusion supportXx_NEWLINE_xXWithin 72 h of initiating study treatment: Absolute neutrophil count (ANC) >= 1000/mm^3; Note: transfusions of blood and blood products as well as growth factor support are prohibited within 14 days prior to the first dose of study treatmentXx_NEWLINE_xXAbsolute neutrophil count >= 1000/mcLXx_NEWLINE_xXGranulocyte count >= 1000/mm^3 (within 16 days before starting therapy)Xx_NEWLINE_xXAbsolute neutrophil count >= 1000/mcLXx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1000 cells/mm^3, unless cytopenias due to non-Hodgkin lymphoma (NHL) (i.e., bone marrow involvement or splenomegaly)Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000Xx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1000 uLXx_NEWLINE_xXSubjects with an absolute neutrophil count (ANC) < 1000 cells/mm3; growth factors may not be used to meet ANC eligibility criteriaXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) ? 1000/mm3 (screening ANC should be independent of growth factor support for ? 1 week)Xx_NEWLINE_xXParticipants with an absolute neutrophil count (ANC) < 1000 cells/mm^3 at time of screening evaluation; growth factor may not be used to meet ANC eligibility criteria within 14 days of obtaining screening evaluationXx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1000/mm^3 without growth factors or transfusionsXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mcLXx_NEWLINE_xXObtained =< 21 days prior to registration: Absolute neutrophil count (ANC) >= 1000/uLXx_NEWLINE_xXPeripheral absolute neutrophil count (ANC) >= 1000/mm^3 andXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/ulXx_NEWLINE_xXPHASE I: Absolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/uLXx_NEWLINE_xXAbsolute neutrophil count > 1000/microliterXx_NEWLINE_xXAbsolute neutrophil count (ANC) 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1000/uLXx_NEWLINE_xXabsolute neutrophil count (ANC) > 1000/mm3Xx_NEWLINE_xXCOHORT A: Absolute neutrophil count (ANC) >= 1000/uLXx_NEWLINE_xXCOHORT B: ANC >= 1000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mLXx_NEWLINE_xXAbsolute neutrophil count (ANC) ? 1000 cells/µLXx_NEWLINE_xXAbsolute neutrophil count (ANC) < 1000 cells/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/ul (unsupported)Xx_NEWLINE_xXAbsolute Neutrophil Count (ANC) <1000 within 8 weeks prior to initial cryoablation procedure.Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/ulXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/uLXx_NEWLINE_xXGranulocyte count >= 1000/mm^3 (within 16 days before starting therapy)Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count >= 1000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1000/mcLXx_NEWLINE_xXPeripheral absolute neutrophil count (ANC) >= 1000/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1000/microliter (mcL)Xx_NEWLINE_xXAbsolute neutrophil count >= 1000/mm^3Xx_NEWLINE_xXNeutrophil count >= 1000/mm^3; (no growth factors within 5 days prior to first dose of the study drug)Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) ? 1.0 (1000/mm3)Xx_NEWLINE_xXPatient has an absolute neutrophil count of < 1000 within 5 days before enrollmentXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) greater than 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1000Xx_NEWLINE_xXLymphocytes >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000Xx_NEWLINE_xXWithin one week of study entry: Absolute neutrophil count (ANC) >= 1000 cells/mm^3Xx_NEWLINE_xXAbsolute neutrophil count >= 1000 cells/mm^3Xx_NEWLINE_xXNeutrophils > 1000/uLXx_NEWLINE_xXNeutrophils > 1000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000 cells/mm^3Xx_NEWLINE_xXAbsolute neutrophil count >= 1000/uLXx_NEWLINE_xXNeutrophil count >= 1000 prior to biopsyXx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1000/mm^3Xx_NEWLINE_xXGranulocyte count >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count > = 1000 /mm³Xx_NEWLINE_xXAbsolute neutrophil count greater than 1000/mm^3 without the support of filgrastimXx_NEWLINE_xXAbsolute neutrophil count (ANC): >= 1000/uL (~ 1 x 10^9/L)Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >1000/?L and Platelet count > 25,000/?LXx_NEWLINE_xXAbsolute neutrophil count >= 1000/mL (obtained =< 14 days prior to registration)Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/microliterXx_NEWLINE_xXAbsolute neutrophil count greater than 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000Xx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1000Xx_NEWLINE_xXPatient has an absolute neutrophil count of less 1000 within 14 days before enrollmentXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1.0 x 10^9/L (>= 1000 per mm^3)Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000 cells/mm^3Xx_NEWLINE_xXAbsolute neutrophil count >= 1000 uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000 cells/mm^3 and platelet count >= 60 K when maintenance lenalidomide is started (day 100 post-transplant)Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count ? 1000/mm3Xx_NEWLINE_xXAbsolute neutrophil count greater than or equal to 1000/mm^3 without the support of filgrastimXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/uL obtained =< 14 days prior to registrationXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1000/ulXx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1000 unless impairment due to organ involvement by lymphomaXx_NEWLINE_xXAbsolute neutrophil count greater than or equal to 1000/mclXx_NEWLINE_xXAbsolute neutrophil count (ANC) equal or greater to 1000 without growth factor support for at least 5 daysXx_NEWLINE_xXAbsolute neutrophil count of > 1000/ulXx_NEWLINE_xXNeutrophil count > 1000/mm^3Xx_NEWLINE_xXANC 1000 cells/mLXx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1000 cells/mlXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC): >= 1000/uL (~0.5 x 10^9/L)Xx_NEWLINE_xXAbsolute neutrophil count greater than 1000/mm^3 without the support of filgrastimXx_NEWLINE_xXAbsolute neutrophil count greater than 1000/mm^3 without the support of filgrastimXx_NEWLINE_xXAbsolute neutrophil count: >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) < 1000/mclXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/ulXx_NEWLINE_xXAbsolute neutrophil count > 1000/uLXx_NEWLINE_xXAbsolute neutrophil count greater than 1000/mm^3 without the support of filgrastimXx_NEWLINE_xXAbsolute neutrophil count <1000/mLXx_NEWLINE_xXANC ? 1000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) must be >= 1000/mm^3Xx_NEWLINE_xXANC ?1000/mm³Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXPeripheral absolute neutrophil count (ANC) >= 1000/uLXx_NEWLINE_xXPeripheral absolute neutrophil count (ANC) >= 1000/mm^3; \r\n* Note: must be > 7 days from use of hematopoietic growth factor or 21 days from pegfilgastrimXx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count greater than 1000/mm^3 without the support of filgrastimXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/uLXx_NEWLINE_xXPeripheral absolute neutrophil count (ANC) >= 1000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/ulXx_NEWLINE_xXAbsolute neutrophil count > 1000 cells/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/uL, unless due to bone marrow involvement by lymphomaXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/?LXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/uLXx_NEWLINE_xXANC > 1000 /mlXx_NEWLINE_xXAbsolute neutrophil count (ANC) greater than or equal to (?) 1000/microliterXx_NEWLINE_xXAbsolute neutrophil count >= 1000/uLXx_NEWLINE_xXAbsolute neutrophil count > 1000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1000/uL not supported by transfusionsXx_NEWLINE_xXAbsolute neutrophil count greater than 1000/mm^3 without the support of filgrastimXx_NEWLINE_xXAbsolute neutrophil count greater than 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) ? 1000/mm³ within 21 days prior to randomization. Screening ANC should be independent of growth factor support for ? 1 week.Xx_NEWLINE_xXPatients must have absolute neutrophil count (ANC) >= 1000/uL; Neupogen can be given prior to start of SGN-35 (brentuximab vedotin) and during SGN-35 treatment to achieve target ANC >= 1000/uLXx_NEWLINE_xXANC >= 1000/uLXx_NEWLINE_xXNeutrophils > 1000/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1000/mcLXx_NEWLINE_xXAbsolute neutrophil count >= 1000/mm^3Xx_NEWLINE_xXANC of >1000/mm3Xx_NEWLINE_xXANC of >1000/mm3 independent of G-CSFXx_NEWLINE_xXANC of >1000/mm3 independent of G-CSFXx_NEWLINE_xXAplastic anemia with absolute neutrophil count (ANC) < 1000 and transfusion dependent after they failed immunosuppression therapyXx_NEWLINE_xXAbsolute neutrophil count >1000 cells/mm^3 without growth factors for 7 days.Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count greater than 1000/mm^3 without the support of filgrastimXx_NEWLINE_xXAbsolute neutrophil count greater than 1000/mm^3 without the support of filgrastimXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/uLXx_NEWLINE_xXNeutropenia as defined by an absolute neutrophil count (ANC) of < 1000 cells/mmXx_NEWLINE_xXNeutropenic patient with absolute neutrophil count (ANC) less than 1000 cells/mm^3Xx_NEWLINE_xXPeripheral absolute neutrophil (ANC) >= 1000/uLXx_NEWLINE_xXANC > 1000/uLXx_NEWLINE_xXAbsolute neutrophil count <1000/mLXx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1000/mm^3 without growth factors or transfusionsXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/ul without growth factor or transfusional supportXx_NEWLINE_xXPatient currently with neutropenia (absolute neutrophil count <1000) within 6 weeks screeningXx_NEWLINE_xXHematological: Total absolute phagocyte count ?1000/?LXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXGranulocyte count > 1000/mm^3Xx_NEWLINE_xXNeutrophil count >= 1000/mcLXx_NEWLINE_xXANC ?1000/µLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1.0 x 10^9/L (> 1000 per mm^3)Xx_NEWLINE_xXAbsolute neutrophil count (ANC) ? 1000/uLXx_NEWLINE_xXAbsolute neutrophil count ? 1000/mm3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) of =< 1000Xx_NEWLINE_xXWithin 14 days prior to study entry: Absolute neutrophil count (ANC) > 1000/mm^3Xx_NEWLINE_xX- Neutrophil count of > 1000/mm3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000/mm^3Xx_NEWLINE_xXAbsolute neutrophil count >= 1000/mcLXx_NEWLINE_xXAt the discretion of the operating surgeon, absolute neutrophil count (ANC) > 1000/mclXx_NEWLINE_xXAt the discretion of the physician, absolute neutrophil count (ANC) > 1000/mclXx_NEWLINE_xXPeripheral absolute neutrophil count (ANC) >= 1000/uL (must not have received G-CSF [filgrastim] within the prior 7 days)Xx_NEWLINE_xXANC ? 1000/mm3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1000 cells/uLXx_NEWLINE_xX- Neutrophil count of > 1000/mm3Xx_NEWLINE_xXAbsolute neutrophil count > 1000/mm3Xx_NEWLINE_xXAbsolute neutrophil count > 1000/uLXx_NEWLINE_xX